| Mrs Tyrette Herrington Bodine, LCSW | |
|
1585 3rd St Bldg 285, Fort Polk, LA 71459-5102 | |
| (337) 531-4170 | |
| Not Available |
| Full Name | Mrs Tyrette Herrington Bodine |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 1585 3rd St Bldg 285, Fort Polk, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740546639 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 10254 (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Tyrette Herrington Bodine, LCSW 109 Noah Haymon Rd, Leesville, LA 71446-8696 Ph: (337) 424-5473 | Mrs Tyrette Herrington Bodine, LCSW 1585 3rd St Bldg 285, Fort Polk, LA 71459-5102 Ph: (337) 531-4170 |
News Archive
The Critical Path Institute (C-Path) and CDISC are pleased to announce the release of a global Foundational Standard that describes how to represent data for the natural history and efficacy studies conducted in animals submitted to applications under the U.S. Food and Drug Administration (FDA) regulations commonly known as the Animal Rule.
Hypertrophic cardiomyopathy (HCM), a genetic form of heart disease with thick heart walls, is the most common cause of sudden death in patients under 50. While only a minority of patients with HCM are at risk, the implantable cardioverter-defibrillator (ICD) can effectively prevent sudden death in those patients.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
People born with heart defects who survive into adulthood may be at higher risk of developing dementia, particularly dementia that starts before 65 years of age, according to new research in the American Heart Association's journal Circulation.
The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.
› Verified 3 days ago
Mark Bradley, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Bjach, Fort Polk, LA 71459 Phone: 337-531-3942 | |
Hannah Klein, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 337-531-3922 | |
Ms. Cheryl Langley Castille, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 337-531-1667 | |
Sharon Hitchens, LCSW-BACS Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 337-531-0289 | |
Heather Hoosier, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 337-531-4027 | |
Miss Emily Druhot, LISW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 337-531-2506 Fax: 337-531-2574 | |
Mrs. Lisa Karen Aycock, LMSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 337-531-3118 |